AKT1 and pancreatic neoplasm: To confirm the roles of PI3K/Akt and MEK/ERK pathways on pancreatic cancer cells, we treated BxPC-3 and PANC-1 cells with PI3K inhibitor LY294002 and MEK inhibitor PD98059, respectively.